Product Information for the Patient User
Alluzience, 200 units Speywood/ml, injectable solution
Toxin type A fromClostridium botulinum– hemagglutinin complex
Read this entire product information carefully before starting to use this medication, as it contains important information for you.
1. What is Alluzience and for what it is used
2. What you need to know before starting to use Alluzience
3. How to use Alluzience
4. Possible adverse effects
5. Storage of Alluzience
6. Contents of the package and additional information
Alluziencecontains a substance, botulinum toxin A, which causes muscles to relax.Alluzience acts on the connection between nerves and muscles, blocking the release of a chemical messenger called acetylcholine at the nerve endings. This phenomenon prevents muscle contraction. Muscle relaxation is temporary and recovers gradually.
Some people feel unwell when wrinkles appear on their face. Alluzience may be used in adults under 65 years old for the temporary improvement of the appearance of moderate to severe glabellar lines (vertical expression lines between the eyebrows).
No use Alluzience:
Warnings and precautions
Consult your doctor before starting to use this medication:
This information will help your doctor make a decision about the risks and benefits of your treatment.
Very rarely, side effects have been reported with botulinum toxin possibly related to the spread of the toxin's effect to distant locations from the injection site (e.g., muscle weakness, difficulty swallowing, or unwanted food or liquids in the airways).
Seek medical attention immediately if you experience difficulty swallowing, speaking, or breathing.
When using Alluzience in the muscles around the eye, your eyes may dry, which can damage the surface of your eyes. To prevent this, you may need a protective treatment with eye drops, ointment, or a protective shield that closes the eye. Your doctor will tell you if this is necessary.
When botulinum toxin has been used at intervals more frequently than 3 months or at higher doses to treat other conditions, it has been observed very rarely that antibodies are produced. The formation of neutralizing antibodies may reduce the effectiveness of the treatment.
If you visit your doctor for any reason, make sure to inform them that you are being treated with Alluzience.
Children and adolescents
Alluzience is not indicated for patients under 18 years of age.
Other medications and Alluzience
Inform your doctor if you are taking, have taken recently, or may need to take any other medication. This is important because some of these medications may increase the effect of Alluzience:
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, or think you may be pregnant, consult your doctor before using this medication.
Alluzience should not be used during pregnancy or while breastfeeding.
Driving and operating machinery
You may experience transient blurred vision or muscle weakness after treatment with Alluzience. If this occurs, do not drive or operate machinery.
Alluzience contains sodium
This medication contains less than 1 mmol of sodium (23 mg) per vial, which is essentially "sodium-free".
Alluzience can only be administered by doctors with the necessary qualifications and experience in this treatment and who have the appropriate equipment.
Your doctor will apply the injections. A vial of Alluzience must be used for a single patient and a single treatment session.
The recommended dose for the glabellar lines is 50 units of Speywood, administered as 10 units at each of the 5 injection sites on the forehead, the top of the nose, and the eyebrows.
The recommended doses in units of Speywood are different from those of other botulinum toxin preparations.
The effect of the treatment should be appreciated a few days after the injection, and may last up to 6 months.
Your doctor will decide on the appropriate interval between each treatment with Alluzience. This interval must not be less than 3 months.
Use in Children and Adolescents
Alluzience is not indicated for patients under 18 years of age.
If You Use More Alluzience Than You Should
If you receive more Alluzience than necessary, other muscles different from those treated may begin to weaken. Excessive doses may cause paralysis of the respiratory muscles. This may not occur immediately. If these symptoms appear, inform your doctor as soon as possible.
In cases of overdose or accidental administration, call the Toxicological Information Service, phone 91 562 04 20 (indicating the medication and the amount administered).
If you have any other questions about the use of this medication, ask your doctor.
Like all medications, this medication may produce adverse effects, although not everyone will experience them.
Very rarely (it may affect up to 1 in 10,000 people) adverse effects with botulinum toxin have been reported in muscles other than those at the injection site. These effects include excessive muscle weakness, difficulty swallowing, cough, and a sensation of choking when swallowing (if liquids or food enter the airways, respiratory problems, such as pulmonary infections, may occur). If this happens, report it immediately to your doctor.
Seek urgent medical assistance if:
Inform your doctor if you experience any of the following adverse effects:
Very common (may affect more than 1 in 10 people)
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Unknown frequency (cannot be estimated with available data)
Reporting Adverse Effects:
If you experience any type of adverse effect, consult your doctor, even if it is a possible adverse effect not listed in this prospectus. You can also report them directly through the Spanish System for Pharmacovigilance of Medicinal Products for Human Use:https://www.notificaRAM.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not use Alluzience after the expiration date indicated on the label.
Store Alluzience in the refrigerator (2°C - 8°C). Do not freeze. Store the vials in the original packaging to protect them from light.
After removing the vial from the refrigerator, it is recommended to allow the vial to reach room temperature. Alluzience can be stored at temperatures of up to a maximum of 25°C for a single period of 12 hours without openingand protected from light. Alluzience must be discarded if not used within 12 hours after its removal from refrigeration.
Once opened, the product must be used immediately.
The active ingredient is thebotulinum toxin type A*, 200 units Speywood/ml. A vial contains 125 units Speywood in 0.625 ml of solution.
The other components are: L-histidine, sucrose, sodium chloride, polisorbate 80, hydrochloric acid, water for injectable preparations
*Botulinum toxin type A fromClostridium botulinum(a bacterium) – hemagglutinin complex.
The units of botulinum toxin are not interchangeable from one product to another. The recommended doses in units Speywood are different from other botulinum toxin preparations.
Product appearance and packaging contents
Alluzience is an injectable solution. It comes in an individual pack of 1 or 2 vials or in a multiple pack containing 6 individual packs, each containing 2 vials. Some packaging sizes may not be marketed.
Alluzience is a transparent and colourless solution.
Marketing authorization holder and manufacturer
Marketing authorization holder:
Ipsen Pharma
65 quai Georges Gorse
92100 Boulogne-Billancourt
France
Manufacturer:
Ipsen Manufacturing Ireland Limited
Blanchardstown Industrial Park
Blanchardstown
Dublin 15
Ireland
You can request more information about this medicine by contacting the local representative of the Marketing Authorization Holder:
Local representative:
Laboratorios Galderma SA
Serrano Galvache, 56.
28033 Madrid - Spain
Phone: 902 02 75 95
Last review date of this leaflet:November 2022
Other sources of information
The detailed and updated information about this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) http://www.aemps.gob.es/.
-----------------------------------------------------------------------------------------------------------------
This information is intended solely for healthcare professionals:
Dosage and administration:
See section 3 of the Patient Information Leaflet.
Special precautions for disposal and other handling
Follow the usage, handling, and disposal instructions strictly.
RECOMMENDATIONS FOR DISPOSAL OF CONTAMINATED MATERIALS
Immediately after treating the patient, any unused Alluzience (in the vial or in the syringe) must be inactivated with a diluted sodium hypochlorite solution (1% available chlorine).
Any spilled Alluzience must be cleaned with an absorbent cloth soaked in a diluted sodium hypochlorite solution.
Used vials, syringes, and materials must not be emptied and must be disposed of in suitable containers and disposed of in accordance with local regulations.
RECOMMENDATIONS IN CASE OF ACCIDENT DURING HANDLING OF BOTULINUM TOXIN
Follow these usage, handling, and disposal instructions strictly.
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.